|
|
|
|
Genta commences Phase 2 trial of tesetaxel on first subject
Genta Incorporated (OTCBB: GETA) announced that the Company has initiated treatment of the first subject in a new Phase 2 trial of tesetaxel in advanced melanoma.Tesetaxel is the Companys newest clinical-stage small molecule. As a late Phase 2 oncology...
|
|
|
Genta commences treatment in tesetaxel Phase 2 trial for advanced melanoma
Genta Incorporated (OTCBB: GETA) announced that the Company has initiated treatment of the first subject in a new Phase 2 trial of tesetaxel in advanced melanoma.Tesetaxel is the Companys newest clinical-stage small molecule. As a late Phase 2 oncology...
|
|
|
Genta Initiates Phase 2 Study of Tesetaxel, the Leading Clinical-Stage Oral Taxane, in Patients with Advanced
- Genta Incorporated (OTCBB: GETA) announced that the Company has initiated treatment of the first subject in a new Phase 2 trial of tesetaxel in advanced melanoma.Tesetaxel is the Company's newest clinical-stage small molecule. As a late Phase 2 oncology...
|
|
|
Genta Initiates Phase 2 Study of Tesetaxel, the Leading Clinical-Stage Oral Taxane, in Patients with Advanced
BERKELEY HEIGHTS, N.J.(BUSINESS WIRE) Genta Incorporated (OTCBB: GETA) announced that the Company has initiated treatment of the first subject in a new Phase 2 trial of tesetaxel in advanced melanoma.Tesetaxel is the Company's newest clinical-stage small...
|
|
|
Genta Initiates Phase 2 Study of Tesetaxel, the Leading Clinical-Stage Oral Taxane, in Patients with Advanced Melanoma
BERKELEY HEIGHTS, N.J.-- (BUSINESS WIRE) -- Genta Incorporated (OTCBB: GETA) announced that the Company has initiated treatment of the first subject in a new Phase 2 trial of tesetaxel in advanced melanoma.Tesetaxel is the Companys newest clinical-stage...
|
|
|
Genta Initiates Phase 2 Study of Tesetaxel, the Leading Clinical-Stage Oral Taxane, in Patients with Advanced Melanoma
Companies mentioned in this article: Genta Incorporated BERKELEY HEIGHTS, N.J.-- (BUSINESS WIRE) -- Genta Incorporated (OTCBB: GETA) announced that the Company has initiated treatment of the first subject in a new Phase 2 trial of tesetaxel in advanced...
|
|
|
Genta Initiates Phase 2 Study of Tesetaxel, the Leading Clinical-Stage Oral Taxane, in Patients with Advanced
Companies mentioned in this article: Genta Incorporated BERKELEY HEIGHTS, N.J.-- (BUSINESS WIRE) -- Genta Incorporated (OTCBB: GETA) announced that the Company has initiated treatment of the first subject in a new Phase 2 trial of tesetaxel in advanced...
|
|
|
Genta Initiates Phase 2 Study of Tesetaxel, the Leading Clinical-Stage Oral Taxane, in Patients with Advanced
Genta Incorporated (OTCBB: GETA) announced that the Company has initiated treatment of the first subject in a new Phase 2 trial of tesetaxel in advanced melanoma.Tesetaxel is the Companys newest clinical-stage small molecule. As a late Phase 2 oncology...
|
|
|
PREVIEW-Sanofi Q4 seen up, cautious for 2010
t 0730 GMT * Q4 adj.net seen up 3.5 pct at 1.684 bln euros * Q4 sales seen up 4 pct at 7.371 bln ($10.23 billion) * 2010 EPS forecasts from dip to low single-digit growth * Updates on generics, Lovenox, Merial-ISP JV PARIS, Feb 5 (Reuters) - French drugmaker...
|
|
|
Research and Markets: The Biotech Company League Table: Fortunes of the Top 100 Biotech Companies Involved in Human Healthcare on the Basis of Product
45 AM DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/e308ab/the_biotech_compan) has announced the addition of the "The Biotech Company League Table" report to their offering.The worlds first biotechnology company,...
|
|
|
Research and Markets: Drive the Roadmap for Success in Oncology as Global Oncology Market is Projected to Outg
Research and Markets (http://www.researchandmarkets.com/research/d7939f/roadmap_for_succes) has announced the addition of the 'Roadmap for Success in Oncology' report to their offering.The worldwide oncology market is projected to outgrow the rest of the...
|
|
|
ResearchPoint & Azaya Therapeutics Announce First Patient Enrolled in Phase I Clinical Study
- ResearchPoint and Azaya Therapeutics, Inc.are proud to announce the study initiation and enrollment of the first patient in the phase I clinical study of ATI-1123, a new formulation of docetaxel. ATI-1123 has the same active ingredient as the FDA...
|
|
|
Overcoming Taxane Resistance in Cancer
Proteomics study reveals a protein that, when suppressed, makes cancers more susceptible to chemotherapy BOSTON, Jan.25 /PRNewswire-USNewswire/ -- Taxanes, a group of cancer drugs that includes paclitaxel (Taxol) and docetaxel (Taxotere), have become...
|
|
|
Analytical Tool - Lung Cancer
is a premium combo product of 'Competitive Outlook on Lung Cancer Drug Development - The Missing Handbook to New Product Planning and Portfolio Planning' and 'Lung Cancer Drug Pipeline Update 2010'.According to market analytical studies, the therapeutic lung...
|
|
|
ResearchPoint & Azaya Therapeutics Announce First Patient Enrolled In Phase I Clinical Study
ResearchPoint and Azaya Therapeutics, Inc.are proud to announce the study initiation and enrollment of the first patient in the phase I clinical study of ATI-1123, a new formulation of docetaxel. ATI-1123 has the same active ingredient as the FDA approved...
|
|
|
Proteomics Study Reveals A Protein That, When Suppressed, Makes Cancers More Susceptible To Chemotherapy
Taxanes, a group of cancer drugs that includes paclitaxel (Taxol) and docetaxel (Taxotere), have become front-line therapy for a variety of metastatic cancers.But as with many chemotherapy agents, resistance can develop, a frequent problem in breast,...
|
|
|
Medical News: Proteomics Study Reveals A Protein That, When Suppressed, Makes Cancers More Susceptible To Chemotherapy
Taxanes, a group of cancer drugs that includes paclitaxel (Taxol) and docetaxel (Taxotere), have become front-line therapy for a variety of metastatic cancers.But as with many chemotherapy agents, resistance can develop, a frequent problem in breast,...
|
|
|
Medical News: ResearchPoint & Azaya Therapeutics Announce First Patient Enrolled In Phase I Clinical Study
ResearchPoint and Azaya Therapeutics, Inc.are proud to announce the study initiation and enrollment of the first patient in the phase I clinical study of ATI-1123, a new formulation of docetaxel. ATI-1123 has the same active ingredient as the FDA approved...
|
|
|
Protein may Help Overcome Taxane Resistance in Cancer Drugs: Discovery
Category: Drug News Font Size A protein involved in taxane resistance, a group of cancer drugs that includes paclitaxel (Taxol) and docetaxel (Taxotere) have been discovered by Scientists at Children's Hospital Boston, and has become front-line therapy...
|
|
|
Research and Markets: According to Market Analytical Studies, the Therapeutic Lung Cancer Drug Market Is Predicted to Exceed $4 Billion between 20
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/68e976/analytical_tool) has announced the addition of the "" report to their offering.Analytical Tool - Lung Cancer is a premium combo product of "Competitive Outlook...
|
|
|
Research and Markets: According to Market Analytical Studies, the Therapeutic Lung Cancer Drug Market Is Predicted to Exceed $4 Billion between 2010 and 2015
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/68e976/analytical_tool) has announced the addition of the "Analytical Tool - Lung Cancer - 2010" report to their offering.Analytical Tool - Lung Cancer is a premium...
|
|
|
Research and Markets: According to Market Analytical Studies, the Therapeutic Lung Cancer Drug Market Is Predicted to Exceed $4 Billion between 2010 and 2015
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/68e976/analytical_tool) has announced the addition of the "" report to their offering.Analytical Tool - Lung Cancer is a premium combo product of "Competitive Outlook...
|
|
|
Research and Markets: According to Market Analytical Studies, the Therapeutic Lung Cancer Drug
BusinessWire - Research and Markets (http://www.researchandmarkets.com/research/68e976/analytical_tool) has announced the addition of the 'Analytical Tool - Lung Cancer - 2010' report to their offering.Analytical Tool - Lung Cancer is a premium combo product...
|
|
|
Research and Markets: According to Market Analytical Studies, the Therapeutic Lung Cancer Drug Market Is Predi
Research and Markets (http://www.researchandmarkets.com/research/68e976/analytical_tool) has announced the addition of the 'Analytical Tool - Lung Cancer - 2010' report to their offering.Analytical Tool - Lung Cancer is a premium combo product of ...
|
|
|
New discovery may help overcome taxane resistance in cancer
Washington DC: Scientists at Children's Hospital Boston have discovered a protein involved in taxane resistance, a group of cancer drugs that includes paclitaxel (Taxol) and docetaxel (Taxotere) and have become front-line therapy for a variety of...
|
